Galapagos Selects Pre-Clinical Candidate Drug for Cachexia
News Jan 06, 2009
Galapagos NV announced has selected a candidate drug to enter into pre-clinical development in the Company’s cachexia program. This candidate drug is a small molecule that Galapagos has developed in its Selective Androgen Receptor Modulator (SARM) program and which has demonstrated successful Proof of Concept in animal studies.
Galapagos’ pre-clinical candidate G100192 binds very selectively to targeted androgen receptors, potentially enabling the candidate drug to be efficacious without cardiovascular, prostate, or virility side effects traditionally seen in androgen therapies.
Galapagos aims for once-a-day oral dosing that improves muscle mass and function, with minimal effects on hormonal status of cachexia patients. Animal studies completed thus far encourage the Company to continue toward this goal.
In its SARM program, Galapagos’ strategy has been to pursue a first indication in cachexia, with possible second indication in osteoporosis. In February 2008, Galapagos announced that the SARM lead compound had limited bioavailability. Thereafter, its research group at the Biocitech Park in Romainville obtained a breakthrough in potency and oral bioavailability, leading to a pre-clinical candidate within 10 months.
G100192 is a novel compound for which patents are pending, providing freedom to operate. This program is an addition to the Company’s portfolio of unpartnered R&D programs that address known drug targets, which also includes an integrin receptor antagonist (IRA) program in bone metastasis and Nanocort©, a liposome formulation of prednisolone for acute flares in rheumatoid arthritis and multiple sclerosis.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018